SWOG A Randomized Phase II Trial of ASTX727 with Standard Duration versus Shorter Duration of Venetoclax in Genomically Heterogenous AML Among Adults Aged 60 or Older and Less Fit for Intensive Therapy: A MyeloMATCH Substudy Adult CIRB - Late Phase Emphasis Active Available to Open